TN2018000172A1 - Pd1 and/or lag3 binders. - Google Patents
Pd1 and/or lag3 binders.Info
- Publication number
- TN2018000172A1 TN2018000172A1 TNP/2018/000172A TN2018000172A TN2018000172A1 TN 2018000172 A1 TN2018000172 A1 TN 2018000172A1 TN 2018000172 A TN2018000172 A TN 2018000172A TN 2018000172 A1 TN2018000172 A1 TN 2018000172A1
- Authority
- TN
- Tunisia
- Prior art keywords
- molecules
- lag3
- treating
- lag3 binders
- isvds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Photoreceptors In Electrophotography (AREA)
- Ceramic Products (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257009P | 2015-11-18 | 2015-11-18 | |
| PCT/US2016/062394 WO2017087589A2 (en) | 2015-11-18 | 2016-11-17 | Pd1 and/or lag3 binders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2018000172A1 true TN2018000172A1 (en) | 2019-10-04 |
Family
ID=57472067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP/2018/000172A TN2018000172A1 (en) | 2015-11-18 | 2016-11-17 | Pd1 and/or lag3 binders. |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US10323090B2 (https=) |
| EP (1) | EP3377531A2 (https=) |
| JP (3) | JP6817302B2 (https=) |
| KR (3) | KR102220275B1 (https=) |
| CN (1) | CN108473585B (https=) |
| AR (1) | AR106754A1 (https=) |
| AU (3) | AU2016355570B2 (https=) |
| CA (3) | CA3131983C (https=) |
| CL (3) | CL2018001327A1 (https=) |
| CO (1) | CO2018005126A2 (https=) |
| CR (1) | CR20180278A (https=) |
| DO (2) | DOP2018000126A (https=) |
| EA (1) | EA201891165A1 (https=) |
| EC (1) | ECSP18045468A (https=) |
| GE (1) | GEP20217220B (https=) |
| HK (1) | HK1254951A1 (https=) |
| IL (2) | IL300122A (https=) |
| JO (1) | JO3744B1 (https=) |
| MA (1) | MA43260A (https=) |
| MX (2) | MX2018006245A (https=) |
| MY (1) | MY189018A (https=) |
| NI (1) | NI201800061A (https=) |
| PE (1) | PE20181532A1 (https=) |
| PH (1) | PH12018501080A1 (https=) |
| SG (2) | SG10201911035QA (https=) |
| SV (1) | SV2018005694A (https=) |
| TN (1) | TN2018000172A1 (https=) |
| TW (2) | TWI754621B (https=) |
| UA (1) | UA121914C2 (https=) |
| WO (1) | WO2017087589A2 (https=) |
Families Citing this family (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| SG10201805064SA (en) | 2011-06-23 | 2018-07-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| IL318433A (en) | 2014-05-16 | 2025-03-01 | Ablynx Nv | Improved immunoglobulin variable complexes |
| EP4707303A2 (en) | 2014-05-16 | 2026-03-11 | Ablynx NV | Improved immunoglobulin variable domains |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| AU2016355569B2 (en) | 2015-11-18 | 2020-01-02 | Merck Sharp & Dohme Llc | CTLA4 binders |
| IL300122A (en) | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| AU2016357460B2 (en) * | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| HRP20210602T1 (hr) | 2016-06-20 | 2021-05-14 | F-Star Delta Limited | Vezujuće molekule koje vežu pd-l1 i lag-3 |
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| JP7066696B2 (ja) | 2016-10-11 | 2022-05-13 | アジェナス インコーポレイテッド | 抗ｌａｇ－３抗体及びその使用方法 |
| EP3565841A1 (en) | 2017-01-06 | 2019-11-13 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| EA201991673A1 (ru) | 2017-02-10 | 2020-01-17 | Регенерон Фармасьютикалз, Инк. | Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации |
| WO2018217944A1 (en) * | 2017-05-24 | 2018-11-29 | Sutro Biopharma, Inc. | Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
| JP2020522495A (ja) | 2017-05-30 | 2020-07-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
| CN110678200B (zh) | 2017-05-30 | 2024-05-17 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
| ES2965352T3 (es) | 2017-05-30 | 2024-04-12 | Bristol Myers Squibb Co | Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3) |
| CN118027197A (zh) * | 2017-07-06 | 2024-05-14 | 美勒斯公司 | 调节由细胞表达的生物活性的抗体 |
| EP3710478A1 (en) | 2017-11-13 | 2020-09-23 | Crescendo Biologics Limited | Molecules that bind to cd137 and psma |
| CN111712518B (zh) | 2017-11-17 | 2025-03-25 | 默沙东有限责任公司 | 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途 |
| EP3728316B1 (en) | 2017-12-19 | 2025-02-26 | invoX Pharma Limited | Fc binding fragments comprising a pd-l1 antigen-binding site |
| EP3732203A4 (en) * | 2017-12-28 | 2021-12-15 | Nanjing Legend Biotech Co., Ltd. | ANTIBODIES AND THEIR VARIANTS DIRECTED AGAINST PD-L1 |
| CN111699200B (zh) * | 2018-01-15 | 2023-05-26 | 南京传奇生物科技有限公司 | 针对pd-1的单域抗体和其变体 |
| US11655295B2 (en) | 2018-01-18 | 2023-05-23 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-LAG-3 antibody and use thereof |
| WO2019149716A1 (en) * | 2018-01-31 | 2019-08-08 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
| WO2019148412A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| GB201802573D0 (en) * | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| US11661452B2 (en) | 2018-03-20 | 2023-05-30 | WuXi Biologics Ireland Limited | Anti-lag-3 antibody polypeptide |
| EP3768724A4 (en) * | 2018-03-20 | 2022-04-13 | Wuxi Biologics Ireland Limited. | NEW ANTI-PD-1 ANTIBODIES |
| US20210115138A1 (en) * | 2018-03-20 | 2021-04-22 | WuXi Biologics Ireland Limited | Novel bispecific pd-1/lag-3 antibody molecules |
| CN110305215B (zh) * | 2018-03-20 | 2023-11-03 | 基石药业 | 新型抗lag-3抗体多肽 |
| TW202003567A (zh) * | 2018-03-30 | 2020-01-16 | 大陸商南京傳奇生物科技有限公司 | 針對lag-3之單一結構域抗體及其用途 |
| KR20260046525A (ko) | 2018-04-11 | 2026-04-07 | 인히브릭스 바이오사이언스, 인크. | 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도 |
| EP3788079A4 (en) * | 2018-05-03 | 2022-12-21 | Shanghai Epimab Biotherapeutics Co., Ltd. | ANTIBODIES WITH HIGH AFFINITY TO PD-1 AND LAG-3 AND BI-SPECIFIC BINDING PROTEINS PRODUCTION THEREOF |
| CN112236455B (zh) | 2018-05-17 | 2023-05-16 | 南京维立志博生物科技有限公司 | 结合pd-1的抗体及其用途 |
| PT3820569T (pt) | 2018-07-12 | 2025-01-14 | Invox Pharma Ltd | Moléculas de anticorpo que se ligam a pd-l1 e cd137 |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| ES3044118T3 (en) | 2018-07-12 | 2025-11-26 | Invox Pharma Ltd | Antibody molecules that bind cd137 and ox40 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| EP3827019A1 (en) | 2018-07-24 | 2021-06-02 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| CN112739371A (zh) | 2018-07-26 | 2021-04-30 | 百时美施贵宝公司 | 用于治疗癌症的lag-3组合疗法 |
| WO2020064847A1 (en) | 2018-09-26 | 2020-04-02 | Ascendis Pharma A/S | Degradable hyaluronic acid hydrogels |
| CN113166261A (zh) * | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | B7h3单域抗体及其治疗性组合物 |
| LT4445958T (lt) | 2018-10-19 | 2025-12-10 | Bristol-Myers Squibb Company | Kompleksinė terapija, skirta melanomai gydyti |
| WO2020185722A2 (en) | 2019-03-13 | 2020-09-17 | Merck Sharp & Dohme Corp. | Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents |
| US20230051872A1 (en) * | 2019-03-22 | 2023-02-16 | Reflexion Pharmaceuticals, Inc. | Multivalent D-Peptidic Compounds for Target Proteins |
| US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
| EP3715376A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the prevention or treatment of myasthenia gravis |
| EP3715374A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
| EP3715375A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the prevention or treatment of pre-eclampsia |
| JP2022530496A (ja) * | 2019-04-26 | 2022-06-29 | ウーシー バイオロジクス アイルランド リミテッド | Ｐｄ－１およびｌａｇ－３に対する二重特異性抗体 |
| CN110179977A (zh) * | 2019-05-22 | 2019-08-30 | 华中科技大学同济医学院附属同济医院 | 用于治疗黑色素瘤、肺癌或结直肠癌的组合药物制剂 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| US20220267370A1 (en) * | 2019-06-26 | 2022-08-25 | Merck Sharp & Dohme Corp. | Process for Separating Antigen-Binding Polypeptide Monomers Comprising One or More Immunoglobulin Single Variable Domains from Aggregates of Said Monomers |
| CN114144429B (zh) * | 2019-07-16 | 2023-10-13 | 上海药明生物技术有限公司 | 针对pd-1和lag-3的双特异性抗体 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| CN110981958B (zh) * | 2019-08-23 | 2020-10-20 | 四川大学华西医院 | 一种pd-l1抗体 |
| WO2021055994A1 (en) | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
| WO2021057866A1 (zh) * | 2019-09-26 | 2021-04-01 | 苏州克睿基因生物科技有限公司 | 一种单域抗体及包含抗体结构的嵌合抗原受体 |
| WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| US20220411499A1 (en) | 2019-11-08 | 2022-12-29 | Bristol-Myers Squibb Company | LAG-3 Antagonist Therapy for Melanoma |
| CA3161516A1 (en) * | 2019-12-17 | 2021-06-24 | Philip Thomas FROHLICH | Methods of treating iga nephropathy with atrasentan |
| JP2023514152A (ja) | 2020-02-06 | 2023-04-05 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｌ－１０およびその使用 |
| CN113461824A (zh) * | 2020-03-31 | 2021-10-01 | 普米斯生物技术(珠海)有限公司 | 一种构建多特异性抗体的平台 |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| IL300813A (en) | 2020-08-28 | 2023-04-01 | Bristol Myers Squibb Co | LAG-3 antagonist therapy for hepatocellular carcinoma |
| AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| EP4216990A1 (en) | 2020-09-23 | 2023-08-02 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
| KR20230093282A (ko) | 2020-10-23 | 2023-06-27 | 브리스톨-마이어스 스큅 컴퍼니 | 폐암에 대한 lag-3 길항제 요법 |
| WO2022109987A1 (en) * | 2020-11-27 | 2022-06-02 | Shanghai Benemae Pharmaceutical Corporation | Novel anti-lag3 antibodies and methods of making and using the same |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| US20240384350A1 (en) | 2021-01-29 | 2024-11-21 | Board Of Regents, The University Of Texas System | Methods of treating cancer with kinase inhibitors |
| CN117858719A (zh) | 2021-03-29 | 2024-04-09 | 朱诺治疗学股份有限公司 | 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法 |
| EP4319755A4 (en) | 2021-04-08 | 2025-03-26 | Board of Regents, The University of Texas System | Compounds and methods for theranostic targeting of parp activity |
| EP4337694A1 (en) | 2021-05-12 | 2024-03-20 | Dana-Farber Cancer Institute, Inc. | Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof |
| CN113307874B (zh) * | 2021-05-31 | 2022-05-27 | 广州爱思迈生物医药科技有限公司 | 一种抗lag3的抗体及其应用 |
| WO2022266235A1 (en) * | 2021-06-15 | 2022-12-22 | The Trustees Of Columbia University In The City Of New York | Nanobodies against sars-cov-2 for detection of sars-cov-2, and diagnosis, treatment and prevention of infection and disease caused by sars-cov-2 |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| CA3227334A1 (en) | 2021-07-28 | 2023-02-02 | Tiumbio Co., Ltd. | Pharmaceutical composition for preventing or treating tumor, and use thereof |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| CA3224890A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| KR20240135661A (ko) | 2022-01-26 | 2024-09-11 | 브리스톨-마이어스 스큅 컴퍼니 | 간세포성 암종에 대한 조합 요법 |
| WO2023164638A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| JP2025508076A (ja) | 2022-03-08 | 2025-03-21 | アレンティス・セラピューティクス・アクチェンゲゼルシャフト | Ｔ細胞の利用能を向上させるための抗クローディン－１抗体の使用 |
| WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| CN114835810B (zh) * | 2022-03-31 | 2024-01-05 | 浙江特瑞思药业股份有限公司 | 一种抗pd-1纳米抗体及其应用 |
| CN114984207B (zh) * | 2022-05-09 | 2024-01-26 | 浙江特瑞思药业股份有限公司 | 一种抗pd-1纳米抗体制剂 |
| KR20250022071A (ko) | 2022-06-02 | 2025-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | 항체 조성물 및 이의 이용 방법 |
| EP4559932A1 (en) * | 2022-07-20 | 2025-05-28 | Minghui Pharmaceutical (Hangzhou) Limited | Multispecific antibody and use thereof |
| US20240101718A1 (en) * | 2022-09-28 | 2024-03-28 | Incyte Corporation | Anti-pd-1/lag-3 bispecific antibodies and uses thereof |
| EP4626552A1 (en) | 2022-12-01 | 2025-10-08 | MedImmune Limited | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies |
| JP2026501506A (ja) | 2022-12-14 | 2026-01-16 | アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法 |
| EP4638503A1 (en) | 2022-12-21 | 2025-10-29 | Bristol-Myers Squibb Company | Combination therapy for lung cancer |
| EP4665410A1 (en) | 2023-02-17 | 2025-12-24 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| TW202535926A (zh) | 2023-10-30 | 2025-09-16 | 美商再生元醫藥公司 | 穩定抗體配製物 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| TW202541837A (zh) | 2023-12-08 | 2025-11-01 | 日商安斯泰來製藥公司 | 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025184208A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| US12521446B2 (en) | 2024-02-27 | 2026-01-13 | Bristol-Myers Squibb Company | Anti-CEACAM5 antibody drug conjugates |
| WO2025226695A1 (en) | 2024-04-23 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
| CN120118187B (zh) * | 2025-03-19 | 2025-09-19 | 珠海市人民医院 | 一种抗lag3抗体及其应用 |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| EP0663007A1 (en) | 1992-09-29 | 1995-07-19 | The President And Fellows Of Harvard College | Trophic factor having ion channel-inducing activity in neuronal cells |
| US6824779B1 (en) | 1993-07-26 | 2004-11-30 | Dana-Farber Cancer Institute, Inc. | Methods for inhibiting the interaction of B7-2 with its natural ligand |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| US20020006403A1 (en) | 1999-12-14 | 2002-01-17 | Xue-Zhong Yu | CD28-specific antibody compositions for use in methods of immunosuppression |
| US7795002B2 (en) | 2000-06-28 | 2010-09-14 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
| EP2295450B1 (en) | 2000-09-29 | 2015-01-28 | Merck Sharp & Dohme Corp. | Pegylated interleukin-10 |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| DK1345969T3 (da) | 2000-12-26 | 2010-11-29 | Inst Nat Sante Rech Med | Anti-CD28-antistof |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| WO2004038656A2 (en) | 2002-10-24 | 2004-05-06 | Duke University | Binary prediction tree modeling with many predictors |
| WO2004041863A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
| ATE485307T1 (de) | 2003-11-07 | 2010-11-15 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
| AR046833A1 (es) | 2003-11-10 | 2005-12-28 | Schering Corp | Anticuerpos anti-interleuquina-10 |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| US20080267949A1 (en) | 2006-12-05 | 2008-10-30 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| AU2007331672A1 (en) | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
| WO2008132516A1 (en) | 2007-04-26 | 2008-11-06 | Opsona Therapeutics Limited | Toll-like receptor binding epitope and compositions for binding thereto |
| CA2687903C (en) | 2007-05-24 | 2016-09-13 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| EP2650311A3 (en) | 2007-11-27 | 2014-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| EP2285833B1 (en) | 2008-05-16 | 2014-12-17 | Ablynx N.V. | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
| AR073459A1 (es) * | 2008-07-18 | 2010-11-10 | Domantis Ltd | Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| WO2011006915A2 (en) | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
| KR101721187B1 (ko) | 2009-12-23 | 2017-03-29 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 면역원성의 감소 방법 |
| AU2011275749C1 (en) | 2010-07-09 | 2015-09-17 | Aduro Biotech Holdings, Europe B.V. | Agonistic antibody to CD27 |
| CN103917560B (zh) | 2011-03-28 | 2017-05-24 | 埃博灵克斯股份有限公司 | 双特异性抗‑cxcr7免疫球蛋白单可变结构域 |
| WO2012176400A1 (en) | 2011-06-22 | 2012-12-27 | Canon Kabushiki Kaisha | Specimen information acquisition apparatus and specimen information acquisition method |
| SG10201805064SA (en) | 2011-06-23 | 2018-07-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2723771B1 (en) | 2011-06-23 | 2019-09-11 | Ablynx NV | Serum albumin binding proteins |
| PE20141522A1 (es) * | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| WO2013066765A1 (en) | 2011-11-01 | 2013-05-10 | Merck Sharp & Dohme Corp. | Mutation of tup1 in glycoengineered yeast |
| US9670275B2 (en) | 2012-01-23 | 2017-06-06 | Ablynx N.V. | Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| BR112015003851A2 (pt) | 2012-08-21 | 2017-08-08 | Glaxo Group Ltd | composições compreendendo um domínio variável único e mesilato de camostato (cm) |
| WO2014043509A2 (en) | 2012-09-13 | 2014-03-20 | Novartis Ag | Antigen binding molecule with terminal modifications |
| ES2712199T3 (es) | 2012-12-11 | 2019-05-09 | Sekisui Specialty Chemicals Am | Copolímeros de PVOH para aplicaciones de cuidado personal |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| JP6595458B2 (ja) * | 2013-09-20 | 2019-10-23 | ブリストル−マイヤーズ スクイブ カンパニー | 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| CN115160441A (zh) * | 2013-09-26 | 2022-10-11 | 埃博灵克斯股份有限公司 | 双特异性纳米抗体 |
| CN120242030A (zh) | 2013-11-11 | 2025-07-04 | 阿尔莫生物科技股份有限公司 | 将白细胞介素-10用于治疗疾病和病症的方法 |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| EP4707303A2 (en) | 2014-05-16 | 2026-03-11 | Ablynx NV | Improved immunoglobulin variable domains |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| CA2951833C (en) | 2014-07-08 | 2018-01-02 | Umg Abs, Ltd. | Thermoplastic resin composition and molded article thereof |
| TW201618775A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、ｐｄ－１抑制劑及／或ｐｄ－ｌ１抑制劑之治療組合物 |
| CA2957146A1 (en) | 2014-08-12 | 2016-02-18 | Alligator Bioscience Ab | Combination therapies with anti cd40 antibodies |
| MD4733C1 (ro) | 2014-08-19 | 2021-07-31 | Merck Sharp & Dohme Corp | Anticorpi anti-TIGIT |
| KR20250004095A (ko) | 2015-04-17 | 2025-01-07 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| EP3328425B1 (en) | 2015-07-29 | 2021-08-25 | Novartis AG | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer |
| RU2018105846A (ru) | 2015-07-29 | 2019-08-28 | Новартис Аг | Комбинация антагониста pd-1 с ингибитором egfr |
| EP4458417A3 (en) | 2015-08-11 | 2025-02-19 | Wuxi Biologics Ireland Limited | Novel anti-pd-1 antibodies |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| BR112018006237A2 (pt) | 2015-09-29 | 2018-10-09 | Celgene Corp | proteínas de ligação a pd-1 e métodos de uso das mesmas |
| WO2017055404A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
| ES2895034T3 (es) | 2015-10-02 | 2022-02-17 | Hoffmann La Roche | Anticuerpos anti-PD1 y procedimientos de uso |
| CA3003777A1 (en) | 2015-11-18 | 2017-05-26 | Merck Sharp & Dohme Corp. | Pd1/ctla4 binders |
| IL300122A (en) * | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| AU2016355569B2 (en) | 2015-11-18 | 2020-01-02 | Merck Sharp & Dohme Llc | CTLA4 binders |
| UA122079C2 (uk) | 2015-12-04 | 2020-09-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Поліпептид, що специфічно зв'язується з lrp5 і lrp6 |
| IL260021B (en) | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| EP3243832A1 (en) | 2016-05-13 | 2017-11-15 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety |
| RS61510B1 (sr) | 2016-05-18 | 2021-03-31 | Boehringer Ingelheim Int | Anti pd-1 i anti-lag3 antitela za lečenje kancera |
| EP4101447A1 (en) | 2016-06-30 | 2022-12-14 | Nant Holdings IP, LLC | Nant cancer vaccine |
| RU2656181C1 (ru) | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Анти-pd-1-антитела, способ их получения и способ применения |
| MY192158A (en) | 2016-09-14 | 2022-08-03 | Abbvie Biotherapeutics Inc | Anti-pd-1 antibodies and their uses |
| PE20191076A1 (es) | 2016-09-14 | 2019-08-20 | Beijing hanmi pharm co ltd | Anticuerpo que se une especificamente a pd-1 y fragmento funcional del mismo |
| MX2019002867A (es) | 2016-09-19 | 2019-11-12 | Celgene Corp | Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1. |
| EP4516809A3 (en) | 2017-04-05 | 2025-09-03 | F. Hoffmann-La Roche AG | Bispecific antibodies specifically binding to pd1 and lag3 |
-
2016
- 2016-11-17 IL IL300122A patent/IL300122A/en unknown
- 2016-11-17 US US15/353,919 patent/US10323090B2/en active Active
- 2016-11-17 GE GEAP201614812A patent/GEP20217220B/en unknown
- 2016-11-17 TW TW105137705A patent/TWI754621B/zh not_active IP Right Cessation
- 2016-11-17 SG SG10201911035QA patent/SG10201911035QA/en unknown
- 2016-11-17 KR KR1020197028947A patent/KR102220275B1/ko active Active
- 2016-11-17 UA UAA201806765A patent/UA121914C2/uk unknown
- 2016-11-17 KR KR1020207036090A patent/KR102317574B1/ko active Active
- 2016-11-17 CA CA3131983A patent/CA3131983C/en active Active
- 2016-11-17 SG SG11201804178YA patent/SG11201804178YA/en unknown
- 2016-11-17 MA MA043260A patent/MA43260A/fr unknown
- 2016-11-17 HK HK18114055.3A patent/HK1254951A1/zh unknown
- 2016-11-17 MX MX2018006245A patent/MX2018006245A/es unknown
- 2016-11-17 CR CR20180278A patent/CR20180278A/es unknown
- 2016-11-17 CN CN201680079323.1A patent/CN108473585B/zh active Active
- 2016-11-17 MY MYPI2018000773A patent/MY189018A/en unknown
- 2016-11-17 TW TW111102788A patent/TW202216787A/zh unknown
- 2016-11-17 CA CA3004748A patent/CA3004748C/en active Active
- 2016-11-17 JO JOP/2016/0244A patent/JO3744B1/ar active
- 2016-11-17 KR KR1020187016800A patent/KR102194188B1/ko active Active
- 2016-11-17 JP JP2018525608A patent/JP6817302B2/ja active Active
- 2016-11-17 PE PE2018000983A patent/PE20181532A1/es unknown
- 2016-11-17 EA EA201891165A patent/EA201891165A1/ru unknown
- 2016-11-17 CA CA3132021A patent/CA3132021C/en active Active
- 2016-11-17 TN TNP/2018/000172A patent/TN2018000172A1/en unknown
- 2016-11-17 WO PCT/US2016/062394 patent/WO2017087589A2/en not_active Ceased
- 2016-11-17 AU AU2016355570A patent/AU2016355570B2/en active Active
- 2016-11-17 EP EP16805655.4A patent/EP3377531A2/en active Pending
- 2016-11-18 AR ARP160103543A patent/AR106754A1/es not_active Application Discontinuation
-
2018
- 2018-05-08 IL IL259224A patent/IL259224B2/en unknown
- 2018-05-15 CO CONC2018/0005126A patent/CO2018005126A2/es unknown
- 2018-05-15 SV SV2018005694A patent/SV2018005694A/es unknown
- 2018-05-15 NI NI201800061A patent/NI201800061A/es unknown
- 2018-05-17 CL CL2018001327A patent/CL2018001327A1/es unknown
- 2018-05-18 PH PH12018501080A patent/PH12018501080A1/en unknown
- 2018-05-18 MX MX2023001356A patent/MX2023001356A/es unknown
- 2018-05-18 DO DO2018000126A patent/DOP2018000126A/es unknown
- 2018-06-14 EC ECIEPI201845468A patent/ECSP18045468A/es unknown
-
2019
- 2019-05-17 US US16/415,455 patent/US11168135B2/en active Active
- 2019-05-17 US US16/415,530 patent/US11155619B2/en active Active
- 2019-05-17 US US16/415,496 patent/US11168136B2/en active Active
- 2019-09-27 JP JP2019176483A patent/JP6845905B2/ja active Active
-
2020
- 2020-03-27 AU AU2020202177A patent/AU2020202177B2/en active Active
- 2020-03-30 AU AU2020202238A patent/AU2020202238B2/en active Active
- 2020-09-29 CL CL2020002521A patent/CL2020002521A1/es unknown
- 2020-09-30 CL CL2020002531A patent/CL2020002531A1/es unknown
- 2020-12-17 JP JP2020209140A patent/JP7184866B2/ja active Active
-
2021
- 2021-01-08 DO DO2021000005A patent/DOP2021000005A/es unknown
- 2021-10-08 US US17/497,597 patent/US12351630B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501080A1 (en) | Pd1 and/or lag3 binders | |
| PH12018501079A1 (en) | Ctla4 binders | |
| JO3740B1 (ar) | روابط pd1/ctla4 | |
| ZA201901066B (en) | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof | |
| ZA201801789B (en) | Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof | |
| EP4417263A3 (en) | Cd3 binding antibodies | |
| IL259082A (en) | Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof | |
| MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
| WO2016207273A3 (en) | Multispecific antigen binding proteins | |
| WO2015197598A3 (en) | Multispecific antigen binding proteins | |
| NZ748976A (en) | Bispecific binding proteins and uses thereof | |
| PH12015500752A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 | |
| MX2019000963A (es) | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus metodos de uso. | |
| MX2017007747A (es) | Anticuerpos para il-17c. |